ImmunityBio Inc (IBRX)
(19% Negative) ImmunityBio Inc (IBRX) Announces Delay in million Trials for situ (NMIBC CIS) Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations
(19% Negative) ImmunityBio Inc (IBRX) Announces Delay in million Trials for situ (NMIBC CIS) Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations
📋 ImmunityBio Inc (IBRX) - Clinical Trial Update
Filing Date: 2026-01-15
Accepted: 2026-01-15 08:35:47
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (ImmunityBio Inc):
💼 Business Developments:
Structured Data: